CN113413439B - Traditional Chinese medicine formula for treating Alzheimer's disease and preparation method of compound preparation of traditional Chinese medicine formula - Google Patents
Traditional Chinese medicine formula for treating Alzheimer's disease and preparation method of compound preparation of traditional Chinese medicine formula Download PDFInfo
- Publication number
- CN113413439B CN113413439B CN202110786360.9A CN202110786360A CN113413439B CN 113413439 B CN113413439 B CN 113413439B CN 202110786360 A CN202110786360 A CN 202110786360A CN 113413439 B CN113413439 B CN 113413439B
- Authority
- CN
- China
- Prior art keywords
- dendrobium nobile
- parts
- preparation
- chinese medicine
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 122
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 80
- 238000002360 preparation method Methods 0.000 title claims abstract description 46
- 150000001875 compounds Chemical class 0.000 title claims abstract description 28
- 240000004638 Dendrobium nobile Species 0.000 claims abstract description 99
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 44
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 44
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 42
- 235000011477 liquorice Nutrition 0.000 claims abstract description 41
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 35
- 235000006533 astragalus Nutrition 0.000 claims abstract description 30
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 27
- 241000304195 Salvia miltiorrhiza Species 0.000 claims abstract description 27
- 241001061264 Astragalus Species 0.000 claims abstract description 21
- 210000004233 talus Anatomy 0.000 claims abstract description 21
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 13
- 241001523681 Dendrobium Species 0.000 claims abstract description 12
- 235000017276 Salvia Nutrition 0.000 claims abstract description 11
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 10
- 239000002671 adjuvant Substances 0.000 claims abstract description 10
- 241000037831 Polygonatum sibiricum Species 0.000 claims abstract 2
- 239000000284 extract Substances 0.000 claims description 61
- 239000000243 solution Substances 0.000 claims description 51
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 44
- 239000000843 powder Substances 0.000 claims description 34
- 238000002156 mixing Methods 0.000 claims description 33
- 239000000706 filtrate Substances 0.000 claims description 30
- 239000008187 granular material Substances 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 21
- 238000001914 filtration Methods 0.000 claims description 20
- 239000009636 Huang Qi Substances 0.000 claims description 19
- 238000003756 stirring Methods 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- 230000002829 reductive effect Effects 0.000 claims description 17
- 239000012528 membrane Substances 0.000 claims description 16
- 239000000047 product Substances 0.000 claims description 16
- 239000012752 auxiliary agent Substances 0.000 claims description 15
- 239000000341 volatile oil Substances 0.000 claims description 15
- 239000006187 pill Substances 0.000 claims description 14
- 238000009210 therapy by ultrasound Methods 0.000 claims description 14
- 238000010438 heat treatment Methods 0.000 claims description 13
- 238000009835 boiling Methods 0.000 claims description 12
- 239000008367 deionised water Substances 0.000 claims description 12
- 229910021641 deionized water Inorganic materials 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 12
- 238000010992 reflux Methods 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- 241000756042 Polygonatum Species 0.000 claims description 11
- 239000002244 precipitate Substances 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 8
- 239000011265 semifinished product Substances 0.000 claims description 8
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 6
- 238000010298 pulverizing process Methods 0.000 claims description 6
- 241000238631 Hexapoda Species 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- 239000005913 Maltodextrin Substances 0.000 claims description 4
- 229920002774 Maltodextrin Polymers 0.000 claims description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- 229940107666 astragalus root Drugs 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000005469 granulation Methods 0.000 claims description 4
- 230000003179 granulation Effects 0.000 claims description 4
- 238000000703 high-speed centrifugation Methods 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 229940035034 maltodextrin Drugs 0.000 claims description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 4
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims description 4
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 4
- 238000002791 soaking Methods 0.000 claims description 4
- 238000000967 suction filtration Methods 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims description 2
- 229940080350 sodium stearate Drugs 0.000 claims description 2
- 241000202807 Glycyrrhiza Species 0.000 claims 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims 2
- 229940010454 licorice Drugs 0.000 claims 2
- 239000011259 mixed solution Substances 0.000 claims 2
- 241000212322 Levisticum officinale Species 0.000 claims 1
- 239000012467 final product Substances 0.000 claims 1
- 229940095686 granule product Drugs 0.000 claims 1
- 239000001645 levisticum officinale Substances 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 57
- 229940079593 drug Drugs 0.000 abstract description 47
- RYAHJFGVOCZDEI-UFFNCVEVSA-N Dendrobine Chemical compound C([C@H]1CC[C@@H]2[C@@]31C)N(C)[C@@H]3[C@H]1[C@@H](C(C)C)[C@@H]2C(=O)O1 RYAHJFGVOCZDEI-UFFNCVEVSA-N 0.000 abstract description 8
- 241000721047 Danaus plexippus Species 0.000 abstract description 7
- 230000006872 improvement Effects 0.000 abstract description 6
- 230000008685 targeting Effects 0.000 abstract description 5
- 210000004556 brain Anatomy 0.000 description 24
- 241000700159 Rattus Species 0.000 description 23
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 16
- 102000013498 tau Proteins Human genes 0.000 description 16
- 108010026424 tau Proteins Proteins 0.000 description 16
- 208000024891 symptom Diseases 0.000 description 13
- 230000008859 change Effects 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- -1 pyrrolizidine derivative alkaloid Chemical class 0.000 description 12
- 230000006870 function Effects 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 230000009471 action Effects 0.000 description 10
- 230000003920 cognitive function Effects 0.000 description 9
- 230000002490 cerebral effect Effects 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 210000001320 hippocampus Anatomy 0.000 description 8
- 230000010412 perfusion Effects 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 229930013930 alkaloid Natural products 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000013016 learning Effects 0.000 description 7
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 6
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 6
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 6
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 6
- ZPIKVDODKLJKIN-NSHDSACASA-N Senkyunolide Chemical compound C1CC=CC2=C1[C@H](CCCC)OC2=O ZPIKVDODKLJKIN-NSHDSACASA-N 0.000 description 6
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 6
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 6
- 150000003797 alkaloid derivatives Chemical class 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 6
- 230000030609 dephosphorylation Effects 0.000 description 6
- 238000006209 dephosphorylation reaction Methods 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000004770 neurodegeneration Effects 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 229940126680 traditional chinese medicines Drugs 0.000 description 6
- 101100030375 Dictyostelium discoideum pho2a gene Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 238000011049 filling Methods 0.000 description 5
- 230000015654 memory Effects 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- YOMSJEATGXXYPX-UHFFFAOYSA-N 2-methoxy-4-vinylphenol Chemical compound COC1=CC(C=C)=CC=C1O YOMSJEATGXXYPX-UHFFFAOYSA-N 0.000 description 4
- 101000741929 Caenorhabditis elegans Serine/threonine-protein phosphatase 2A catalytic subunit Proteins 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 4
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 description 4
- 108010012715 Superoxide dismutase Proteins 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- IPZIYGAXCZTOMH-UHFFFAOYSA-N alpha-eudesmol Natural products CC1=CCCC2CCC(CC12)C(C)(C)O IPZIYGAXCZTOMH-UHFFFAOYSA-N 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- WWULHQLTPGKDAM-UHFFFAOYSA-N gamma-eudesmol Natural products CC(C)C1CC(O)C2(C)CCCC(=C2C1)C WWULHQLTPGKDAM-UHFFFAOYSA-N 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 230000000971 hippocampal effect Effects 0.000 description 4
- 230000006951 hyperphosphorylation Effects 0.000 description 4
- OPMNROCQHKJDAQ-FKSUSPILSA-N loline Chemical compound C1C[C@@H]2O[C@H]3[C@H](NC)[C@@H]2N1C3 OPMNROCQHKJDAQ-FKSUSPILSA-N 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 229930182490 saponin Natural products 0.000 description 4
- 150000007949 saponins Chemical class 0.000 description 4
- 235000017709 saponins Nutrition 0.000 description 4
- PHVSWPDOXIQPTN-UHFFFAOYSA-N sedanonic acid Chemical compound CCCCC(=O)C1CCCC=C1C(O)=O PHVSWPDOXIQPTN-UHFFFAOYSA-N 0.000 description 4
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 4
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 3
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 3
- WMBOCUXXNSOQHM-FLIBITNWSA-N (Z)-3-butylidenephthalide Chemical compound C1=CC=C2C(=C/CCC)/OC(=O)C2=C1 WMBOCUXXNSOQHM-FLIBITNWSA-N 0.000 description 3
- KSDSYIXRWHRPMN-UHFFFAOYSA-N 4'-O-beta-D-Galactopyranoside-6''-p-Coumaroylprunin-4',5,7-Trihydroxyflavanone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC(O)=C3C(=O)C2)C=C1 KSDSYIXRWHRPMN-UHFFFAOYSA-N 0.000 description 3
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 3
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- DEMKZLAVQYISIA-ONJCETCRSA-N Liquiritin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc([C@@H]2Oc3c(C(=O)C2)ccc(O)c3)cc1 DEMKZLAVQYISIA-ONJCETCRSA-N 0.000 description 3
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- 206010039966 Senile dementia Diseases 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 210000003710 cerebral cortex Anatomy 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000000916 dilatatory effect Effects 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 3
- 235000001785 ferulic acid Nutrition 0.000 description 3
- 229940114124 ferulic acid Drugs 0.000 description 3
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 3
- 229960004949 glycyrrhizic acid Drugs 0.000 description 3
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 3
- 235000019410 glycyrrhizin Nutrition 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 235000020778 linoleic acid Nutrition 0.000 description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 3
- DEMKZLAVQYISIA-ZRWXNEIDSA-N liquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([C@H]2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-ZRWXNEIDSA-N 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- WMBOCUXXNSOQHM-UHFFFAOYSA-N n-butylidenephthalide Natural products C1=CC=C2C(=CCCC)OC(=O)C2=C1 WMBOCUXXNSOQHM-UHFFFAOYSA-N 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 230000009822 protein phosphorylation Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229930183325 senkyunolide Natural products 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 3
- 229940035893 uracil Drugs 0.000 description 3
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 3
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 3
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 3
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 3
- 235000012141 vanillin Nutrition 0.000 description 3
- 230000024883 vasodilation Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- HDKHYSDETIRMHM-CDGFVBQXSA-N (2r,3r,4r,5r)-4-[(2r,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyoxan-2-yl]oxy-2,3,5,6-tetrahydroxyhexanal Chemical compound O[C@@H]1[C@@H](O)[C@@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 HDKHYSDETIRMHM-CDGFVBQXSA-N 0.000 description 2
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 2
- NXZSUJKPVSDFNF-UHFFFAOYSA-N 1-Acetyl-beta-carboline Chemical compound C12=CC=CC=C2NC2=C1C=CN=C2C(=O)C NXZSUJKPVSDFNF-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- WNZQDUSMALZDQF-UHFFFAOYSA-N 2-benzofuran-1(3H)-one Chemical compound C1=CC=C2C(=O)OCC2=C1 WNZQDUSMALZDQF-UHFFFAOYSA-N 0.000 description 2
- WMBOCUXXNSOQHM-DHZHZOJOSA-N 3-Butylidenephthalide Natural products C1=CC=C2C(=C/CCC)\OC(=O)C2=C1 WMBOCUXXNSOQHM-DHZHZOJOSA-N 0.000 description 2
- JQSVHBFDZXZENO-UHFFFAOYSA-N 3-butyl-4-hydroxy-3h-2-benzofuran-1-one Chemical compound C1=CC(O)=C2C(CCCC)OC(=O)C2=C1 JQSVHBFDZXZENO-UHFFFAOYSA-N 0.000 description 2
- HJXMNVQARNZTEE-UHFFFAOYSA-N Butylphthalide Chemical compound C1=CC=C2C(CCCC)OC(=O)C2=C1 HJXMNVQARNZTEE-UHFFFAOYSA-N 0.000 description 2
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 2
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 235000011201 Ginkgo Nutrition 0.000 description 2
- 244000194101 Ginkgo biloba Species 0.000 description 2
- 235000008100 Ginkgo biloba Nutrition 0.000 description 2
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 2
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- 241001136306 Hydrophiidae Species 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- QGMAWEIDGADSAC-UHFFFAOYSA-N L-Valyl-L-valine anhydride Natural products CC(C)C1NC(=O)C(C(C)C)NC1=O QGMAWEIDGADSAC-UHFFFAOYSA-N 0.000 description 2
- 241000207923 Lamiaceae Species 0.000 description 2
- UPJFTVFLSIQQAV-KOLCDFICSA-N Neocnidilide Chemical compound C1CC[C@H]2[C@H](CCCC)OC(=O)C2=C1 UPJFTVFLSIQQAV-KOLCDFICSA-N 0.000 description 2
- UPJFTVFLSIQQAV-UHFFFAOYSA-N Neocnidilide Natural products C1CCC2C(CCCC)OC(=O)C2=C1 UPJFTVFLSIQQAV-UHFFFAOYSA-N 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010036631 Presenile dementia Diseases 0.000 description 2
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 239000005703 Trimethylamine hydrochloride Substances 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 2
- 229940074360 caffeic acid Drugs 0.000 description 2
- 235000004883 caffeic acid Nutrition 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- ZZAJQOPSWWVMBI-UHFFFAOYSA-N calycosin Chemical compound C1=C(O)C(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZZAJQOPSWWVMBI-UHFFFAOYSA-N 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 2
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- RYAHJFGVOCZDEI-CZKZLRAZSA-N dendrobine Natural products O=C1O[C@@H]2[C@H](C(C)C)[C@H]1[C@H]1[C@@]3(C)[C@@H]2N(C)C[C@H]3CC1 RYAHJFGVOCZDEI-CZKZLRAZSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- OPMNROCQHKJDAQ-UHFFFAOYSA-N festucine Natural products C1CC2OC3C(NC)C2N1C3 OPMNROCQHKJDAQ-UHFFFAOYSA-N 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- HKQYGTCOTHHOMP-UHFFFAOYSA-N formononetin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O HKQYGTCOTHHOMP-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 238000002991 immunohistochemical analysis Methods 0.000 description 2
- 230000036046 immunoreaction Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 2
- 229960004640 memantine Drugs 0.000 description 2
- 230000007087 memory ability Effects 0.000 description 2
- 230000006386 memory function Effects 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 2
- ZCFOBLITZWHNNC-UHFFFAOYSA-N oct-3-en-2-one Chemical compound CCCCC=CC(C)=O ZCFOBLITZWHNNC-UHFFFAOYSA-N 0.000 description 2
- IUCHKMAZAWJNBJ-RCYXVVTDSA-N oleanolic acid 3-O-beta-D-glucosiduronic acid Chemical compound O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O IUCHKMAZAWJNBJ-RCYXVVTDSA-N 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 235000005412 red sage Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- NDVASEGYNIMXJL-UHFFFAOYSA-N sabinene Chemical compound C=C1CCC2(C(C)C)C1C2 NDVASEGYNIMXJL-UHFFFAOYSA-N 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000004622 sleep time Effects 0.000 description 2
- 230000008925 spontaneous activity Effects 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000002636 symptomatic treatment Methods 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- SZYJELPVAFJOGJ-UHFFFAOYSA-N trimethylamine hydrochloride Chemical compound Cl.CN(C)C SZYJELPVAFJOGJ-UHFFFAOYSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical compound N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 description 2
- NDVASEGYNIMXJL-NXEZZACHSA-N (+)-sabinene Natural products C=C1CC[C@@]2(C(C)C)[C@@H]1C2 NDVASEGYNIMXJL-NXEZZACHSA-N 0.000 description 1
- ADHFZEPOBOTKSO-QLTVFDSQSA-N (1R,2S,4R,5'R,6R,7S,8R,9S,12S,13S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane]-3-ol Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CCCCC4CC[C@H]3[C@@H]2C1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 ADHFZEPOBOTKSO-QLTVFDSQSA-N 0.000 description 1
- YDZWHGJRWMQCDP-NKILCQAGSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4ar,6ar,6bs,8as,12as,14ar,14br)-8a-carboxy-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3-hydroxy-4-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-[(2s,3r,4 Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YDZWHGJRWMQCDP-NKILCQAGSA-N 0.000 description 1
- KRZJRNZICWNMOA-GXSJLCMTSA-N (3s,4r)-4,8-dihydroxy-3-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1=CC=C2[C@@H](O)[C@@H](OC)CC(=O)C2=C1O KRZJRNZICWNMOA-GXSJLCMTSA-N 0.000 description 1
- SQEBMLCQNJOCBG-HVHJFMEUSA-N (5s)-3-(hydroxymethyl)-5-methoxy-4-methyl-5-[(e)-2-phenylethenyl]furan-2-one Chemical compound C=1C=CC=CC=1/C=C/[C@]1(OC)OC(=O)C(CO)=C1C SQEBMLCQNJOCBG-HVHJFMEUSA-N 0.000 description 1
- 239000001764 (E)-oct-3-en-2-one Substances 0.000 description 1
- XLFDJKJEYMKLJX-YFHOEESVSA-N (Z)-3-butylidene-7-hydroxyphthalide Chemical compound C1=CC=C(O)C2=C1C(=C/CCC)/OC2=O XLFDJKJEYMKLJX-YFHOEESVSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- WJKQTIOYPFPGQW-VZRGJMDUSA-N 2-methyl-6-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trienyl]cyclohexa-2,5-diene-1,4-dione Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC1=CC(=O)C=C(C)C1=O WJKQTIOYPFPGQW-VZRGJMDUSA-N 0.000 description 1
- ZUKMVCFUUDMOJG-UHFFFAOYSA-N 4-(1-hydroxyhexyl)-2-methoxyphenol Chemical compound CCCCCC(O)C1=CC(OC)=C(O)C=C1 ZUKMVCFUUDMOJG-UHFFFAOYSA-N 0.000 description 1
- SMRPGWBDLOQHOS-UHFFFAOYSA-N 5-[4,5-dihydroxy-6-(hydroxymethyl)-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxy-3,4-dihydroxy-6-[[9-hydroxy-4-(hydroxymethyl)-4,6a,6b,8a,11,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1H-picen-3-yl]oxy]oxane-2-carboxylic acid Chemical compound OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(C(O)C2O)C(O)=O)OC2C(C3C(C4C(C5(CCC6(C)C(O)CC(C)(C)CC6C5=CC4=O)C)(C)CC3)(C)CC2)(C)CO)OC(CO)C(O)C1O SMRPGWBDLOQHOS-UHFFFAOYSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 238000010173 Alzheimer-disease mouse model Methods 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 208000033386 Buerger disease Diseases 0.000 description 1
- 241000269417 Bufo Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 241000212948 Cnidium Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBMORZZOJSDNRQ-UHFFFAOYSA-N Demethoxy,B,HCl-Adriamycin Natural products C1C2C(=C)CCCC2(C)CC2(O)C1=C(C)C(=O)O2 FBMORZZOJSDNRQ-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 235000018142 Hedysarum alpinum var americanum Nutrition 0.000 description 1
- 240000006461 Hedysarum alpinum var. americanum Species 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- LHFKHAVGGJJQFF-UEOYEZOQSA-N Hydroxy-alpha-sanshool Chemical compound C\C=C\C=C\C=C/CC\C=C\C(=O)NCC(C)(C)O LHFKHAVGGJJQFF-UEOYEZOQSA-N 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- YNWXJFQOCHMPCK-UHFFFAOYSA-N Isoliquiritin Natural products OC1C(O)C(O)C(CO)OC1OC(C=C1)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O YNWXJFQOCHMPCK-UHFFFAOYSA-N 0.000 description 1
- GMBQZIIUCVWOCD-UQHLGXRBSA-N Isosarsasapogenin Natural products O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)C[C@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 GMBQZIIUCVWOCD-UQHLGXRBSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- FURUXTVZLHCCNA-UHFFFAOYSA-N Liquiritigenin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-UHFFFAOYSA-N 0.000 description 1
- 238000012347 Morris Water Maze Methods 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- XQWFHGOIUZFQPJ-USTPAGJBSA-N Neoisoliquiritigenin Natural products O=C(/C=C/c1ccc(O)cc1)c1c(O)cc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O2)cc1 XQWFHGOIUZFQPJ-USTPAGJBSA-N 0.000 description 1
- XQWFHGOIUZFQPJ-LXGDFETPSA-N Neoisoliquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C=C1O)=CC=C1C(=O)\C=C\C1=CC=C(O)C=C1 XQWFHGOIUZFQPJ-LXGDFETPSA-N 0.000 description 1
- XQWFHGOIUZFQPJ-UHFFFAOYSA-N Neoisoliquiritin Natural products OC1C(O)C(O)C(CO)OC1OC(C=C1O)=CC=C1C(=O)C=CC1=CC=C(O)C=C1 XQWFHGOIUZFQPJ-UHFFFAOYSA-N 0.000 description 1
- HJBUYKZTEBZNSH-ZRWXNEIDSA-N Neoliquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C(=O)C[C@H](O2)C=3C=CC(O)=CC=3)C2=C1 HJBUYKZTEBZNSH-ZRWXNEIDSA-N 0.000 description 1
- HJBUYKZTEBZNSH-ONJCETCRSA-N Neoliquiritin Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C(=O)C[C@@H](O2)C=3C=CC(O)=CC=3)C2=C1 HJBUYKZTEBZNSH-ONJCETCRSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 238000010826 Nissl staining Methods 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000612118 Samolus valerandi Species 0.000 description 1
- BMWPBKOFJSHJAW-UHFFFAOYSA-N Saponin B Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(OC7OC(CO)C(O)C(O)C7O)C6=O)C(C)(C)C5CCC34C)C2C1)C(=O)O BMWPBKOFJSHJAW-UHFFFAOYSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- WJKQTIOYPFPGQW-UHFFFAOYSA-N Senkyunone Natural products CC(C)=CCCC(C)=CCCC(C)=CCC1=CC(=O)C=C(C)C1=O WJKQTIOYPFPGQW-UHFFFAOYSA-N 0.000 description 1
- QURPLLAPNURGHG-UHFFFAOYSA-N Sibiricoside B Chemical compound O1C2(C(CC(C)CO2)O)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2(O)C3CC=C4CC5OC(C(C1O)O)OC(CO)C1OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OCC(O)C(O)C1O QURPLLAPNURGHG-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- KMJLGCYDCCCRHH-UHFFFAOYSA-N Spathulenol Natural products CC1(O)CCC2(C)C1C3C(CCC2=C)C3(C)C KMJLGCYDCCCRHH-UHFFFAOYSA-N 0.000 description 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- KQAZVFVOEIRWHN-UHFFFAOYSA-N alpha-thujene Natural products CC1=CCC2(C(C)C)C1C2 KQAZVFVOEIRWHN-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000003941 amyloidogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000007131 anti Alzheimer effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229940039856 aricept Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000008335 axon cargo transport Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 229950005197 butylphthalide Drugs 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- PHIQHXFUZVPYII-UHFFFAOYSA-N carnitine Chemical compound C[N+](C)(C)CC(O)CC([O-])=O PHIQHXFUZVPYII-UHFFFAOYSA-N 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 210000001947 dentate gyrus Anatomy 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000706 effect on dopamine Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- FRMCCTDTYSRUBE-HYFYGGESSA-N ent-spathulenol Chemical compound C1CC(=C)[C@H]2CC[C@@](C)(O)[C@@H]2[C@H]2C(C)(C)[C@H]21 FRMCCTDTYSRUBE-HYFYGGESSA-N 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229940108366 exelon Drugs 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 150000008376 fluorenones Chemical class 0.000 description 1
- RIKPNWPEMPODJD-UHFFFAOYSA-N formononetin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC=C2C1=O RIKPNWPEMPODJD-UHFFFAOYSA-N 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229930184727 ginkgolide Natural products 0.000 description 1
- 230000007387 gliosis Effects 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 238000009775 high-speed stirring Methods 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- DXDRHHKMWQZJHT-FPYGCLRLSA-N isoliquiritigenin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O DXDRHHKMWQZJHT-FPYGCLRLSA-N 0.000 description 1
- 235000008718 isoliquiritigenin Nutrition 0.000 description 1
- YNWXJFQOCHMPCK-LXGDFETPSA-N isoliquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C=C1)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O YNWXJFQOCHMPCK-LXGDFETPSA-N 0.000 description 1
- JUTMAMXOAOYKHT-UHFFFAOYSA-N karrikinolide Natural products C1=COC=C2OC(=O)C(C)=C21 JUTMAMXOAOYKHT-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- FURUXTVZLHCCNA-AWEZNQCLSA-N liquiritigenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-AWEZNQCLSA-N 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000004973 motor coordination Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000001777 nootropic effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000011302 passive avoidance test Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
- 229960002582 perindopril Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 150000002987 phenanthrenes Chemical class 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- TXUSTSJRABHHQP-UFGIQYKASA-N pulsatilla saponin D Natural products C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](CO[C@H]2O[C@H]3CC[C@@]4(C)[C@@H](CC[C@]5(C)[C@@H]4CC=C6[C@@H]7CC(C)(C)CC[C@@]7(CC[C@@]56C)C(=O)O)[C@]3(C)O)O[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O)[C@H](O)[C@H](O)[C@H]1O TXUSTSJRABHHQP-UFGIQYKASA-N 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 210000001034 respiratory center Anatomy 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 229930006696 sabinene Natural products 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- PPRSVUXPYPBULA-UHFFFAOYSA-N saponin A Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6=O)C(C)(C)C5CCC34C)C2C1)C(=O)O PPRSVUXPYPBULA-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- DQNGMIQSXNGHOA-UHFFFAOYSA-N senkyunolide-H Natural products C1CC(O)C(O)C2=C1C(=CCCC)OC2=O DQNGMIQSXNGHOA-UHFFFAOYSA-N 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- ASHAUBLELZYXKD-UHFFFAOYSA-N sibirioside A Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC(=O)C=CC=2C=CC=CC=2)O1 ASHAUBLELZYXKD-UHFFFAOYSA-N 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 230000006886 spatial memory Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000007470 synaptic degeneration Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a traditional Chinese medicine formula for treating Alzheimer's disease and a preparation method of a compound preparation thereof, wherein the traditional Chinese medicine formula comprises the following components in parts by weight: 40-50 parts of dendrobium nobile, 15-20 parts of astragalus membranaceus, 15-20 parts of salvia miltiorrhiza, 4-8 parts of polygonatum sibiricum, 4-8 parts of ligusticum wallichii and 2-4 parts of liquorice, wherein the dendrobium nobile is prepared from dendrobium nobile stems and dendrobium nobile flowers in a weight ratio of 5.0-6.5: 1.0-2.0. The dendrobium stem is used as a monarch drug, the astragalus and the salvia are used as ministerial drugs, the ligusticum wallichii and the rhizoma polygonati are used as adjuvant drugs, and the liquorice is used as a conductant drug. The compound traditional Chinese medicine for treating the Alzheimer disease realizes the improvement of the treatment effect of the medicine on the Alzheimer disease through the specific targeting effect and the mutual cross function among the components.
Description
Technical Field
The invention relates to a traditional Chinese medicine formula for treating Alzheimer's disease and a preparation method of a compound preparation thereof, belonging to the technical field of modern traditional Chinese medicines.
Background
Alzheimer Disease (AD) is a neurodegenerative disease commonly seen in the elderly, and its main pathological changes are diffuse atrophy of cerebral cortex, neurofibrillary tangles, and formation of a large number of senile plaques among nerve cells, etc., with progressive cognitive impairment and memory hypofunction as its main clinical symptoms.
With the current increase in the life expectancy of the population of society, the incidence of AD in the elderly population tends to rise dramatically. However, no specific pathogenesis or effective therapeutic method is available so far.
The existing drugs for treating mild-to-moderate alzheimer's disease are donepezil (Aricept) from Pfizer and Eisai, rivastigmine (Exelon) from novain, galantamine (remininyl) from Johnson & Johnson, and memantine (Ebixa) from Lundbeck, respectively. However, the side effects of the western medicine are very obvious. Such as nausea, vomiting, diarrhea, dizziness, insomnia, muscle spasm, fatigue; hallucinations, chaos of consciousness; dizziness, headache, tiredness; anxiety, increased muscle tone, vomiting, etc.
Because the etiology and pathogenesis of the Alzheimer disease are unknown, no specific therapy exists for the treatment, and the symptomatic treatment is mainly used. Including drug therapy to improve cognitive function and memory impairment; symptomatic treatment improves mental symptoms; good nursing and disease progress delaying. The medicine and rehabilitation therapy aims at improving cognition and memory functions, maintaining independent living ability of patients and improving living quality.
At present, AD treatment drugs are only used for improving cognitive functions, single-target drug therapy has limited curative effect clinically, no specific drug for treating Alzheimer disease exists, and intelligence-improving drugs or drugs for improving cognitive functions are currently effective drugs for treating Alzheimer disease. Patients with alzheimer's disease all have a combination of cognitive disorders, and the main purpose of using nootropic or cognitive function-improving drugs is to improve cognitive function and delay the progression of the disease.
Alzheimer's disease is treatable and controllable by drugs and can help patients improve cognitive function and delay disease progression. However, if the patient does not receive or adhere to correct diagnosis and treatment in time, the progress of the disease cannot be controlled, the disease condition completely loses the basic self-care ability after the disease condition is developed to be severe, and the disease often dies due to complications such as bedsore, fracture, pneumonia and the like or due to exhaustion of important organ functions.
Alzheimer's disease generally occurs in the elderly, and has a high incidence due to the central nervous degeneration of the elderly and the massive death of body cells. The disease is strongly related to both genetic and environmental factors. Patients develop memory impairment or personality changes after the onset of disease. At present, the representative medicines of the traditional Chinese medicines for treating the Alzheimer disease in China are as follows: 1. compound sea snake capsule: the medicine mainly contains sea snake live peptide, can directly enter damaged neurons through the barrier of blood brain, has single repairing effect on dopamine neurons, but has no obvious effect on the total effect. 2. A ginkgo leaf preparation: is a natural active substance extracted from folium Ginkgo, including flavonoids or ginkgolides. The medicine is beneficial to improving cerebral blood circulation and promoting cell activity, and can relieve symptoms such as dizziness, memory deterioration and dysphoria caused by Alzheimer disease. But has obvious side effect and certain neurotoxicity and nephrotoxicity after long-term large-scale administration. 3. The brain protein hydrolysate tablet is an active peptide medicine, contains various amino acids and peptide nerve growth factors, and has the effects of nourishing nerves, improving insomnia and relieving headache. The patient needs to take two to about 4 tablets each time, and needs to take the medicine three times a day. The medicine is mainly used as a nutrition adjuvant, has large dosage, and is not suitable for direct treatment. 4. Other finished Chinese medicines are various in types, such as Chinese patent medicines for reducing blood sugar, blood fat and cholesterol, Chinese patent medicines for dilating cerebral vessels, improving cerebral vascular perfusion, Chinese patent medicines for resisting aging and fatigue, improving immunity of human bodies, Chinese patent medicines for regulating nervous systems and exciting hematopoietic system functions and the like. The Chinese patent medicines are mainly used in the fields of cardiovascular and cerebrovascular disease treatment, blood pressure reduction and blood sugar reduction, have the main functions of treating cardiovascular and cerebrovascular diseases, and are only used as auxiliary medicines when treating Alzheimer's disease. Although the Chinese patent medicines are various in types, the efficacy and the effect are too single, the Chinese patent medicines only have auxiliary improvement effect on partial single symptoms, the whole treatment effect cannot be realized, and the application defect in the treatment of the Alzheimer disease is very obvious.
Therefore, the invention provides a multi-effect and multi-target-effect traditional Chinese medicine formula for treating the Alzheimer disease and a compound preparation thereof, which can comprehensively improve the memory, the spatial memory, the learning ability, the cognitive ability and the like of the old, thereby achieving the purpose of radically treating the Alzheimer disease and making up the important defect of the current Chinese patent medicine for treating the Alzheimer disease.
Disclosure of Invention
The invention aims to solve the problems that the existing medicine for treating the Alzheimer disease has unobvious drug effect and more side effects, only has single-target property, lacks of immunoregulation property and the like, and provides a traditional Chinese medicine formula for treating the Alzheimer disease, which has the advantages of remarkable effect, short treatment course, quick response, safety and no toxic or side effect.
The invention also aims to provide a preparation method of the traditional Chinese medicine formula compound preparation.
In order to achieve the purpose, the invention adopts the following technical scheme:
a traditional Chinese medicine formula for treating Alzheimer's disease is characterized by comprising the following components in parts by weight:
40-50 parts of dendrobium nobile, 15-20 parts of astragalus membranaceus, 15-20 parts of salvia miltiorrhiza, 4-8 parts of rhizoma polygonati, 4-8 parts of ligusticum wallichii and 2-4 parts of liquorice, wherein the dendrobium nobile consists of dendrobium stem and dendrobium nobile flowers, and the weight ratio of the dendrobium stem to the dendrobium nobile flowers is 5.0-6.5: 1.0-2.0.
Preferably, the formula consists of the following components in parts by weight:
48 parts of dendrobium nobile, 18 parts of astragalus mongholicus, 18 parts of salvia miltiorrhiza, 7 parts of rhizoma polygonati, 7 parts of ligusticum wallichii and 2 parts of liquorice.
Preferably, the dendrobium nobile lindl in the invention is composed of dendrobium nobile stems and dendrobium nobile flowers, and the weight ratio of the dendrobium nobile stems to the dendrobium nobile flowers is 5.5: 1.5.
the dendrobium nobile lindl is a monarch drug, namely a drug which plays a main treatment role on the main symptoms or main diseases of the prescription in the prescription, is the main attack direction of the prescription, and the efficacy of the dendrobium nobile lindl is the first of the prescription and is an indispensable drug in the prescription. The astragalus and the salvia are ministerial drugs, one is a drug for assisting monarch drug to strengthen treatment of principal disease or principal symptoms, and the other is a drug for treating concurrent disease or concurrent symptoms, and the potency of the drug is smaller than that of the monarch drug. The rhizoma ligustici wallichii and the rhizoma polygonati are adjuvant drugs, namely assisting monarch drugs and ministerial drugs to strengthen the treatment effect, or directly treating secondary concurrent symptoms. The liquorice is a messenger drug, and has the effects of guiding the channels and guiding the medicines in the formula to reach the focus, and is a blending drug, namely a drug with the effect of blending the medicines, and simultaneously the taking taste of the blending drug.
The compound of the invention is a compound traditional Chinese medicine medicament screened based on the modern traditional Chinese medicine pharmacology by adopting the modern new traditional Chinese medicine technology according to the traditional Chinese medicine theory, and the medicament improves the brain cognitive function and prevents the development process of the Alzheimer disease through the ways of neurotransmitter, cerebral vasodilatation, brain metabolism promoting medicaments and the like. The invention realizes the improvement of the treatment effect of the medicine on the Alzheimer disease by the specific directional action and the mutual cross function among the components, and the interaction and the cross effect among the components are realized based on the basic principle, the action and the effect of the traditional Chinese medicine formula and the analysis of the components of the modern traditional Chinese medicine, the targeting action of the medicine, the efficacy and the toxicological evaluation and the like.
Furthermore, the efficacy and action principles of the traditional Chinese medicine components are explained as follows:
dendrobium nobile: dendrobine is one of the marking components of dendrobium nobile. The dendrobium nobile lindl has the highest dendrobium alkaloid content in all dendrobium nobile, and particularly, the dendrobium nobile lindl produced by Guizhou red water has the average dendrobium alkaloid content of more than 0.8 percent and the highest dendrobium alkaloid content of 1.82 percent through detection. (Chinese pharmacopoeia stipulated not less than 0.4%). The dendrobium nobile lindl contains dendrobium nobile lindl alkali, and also contains various effective components such as dendrobium nobile lindl polysaccharide, flavonoid, phenols, phenanthrenes and bibenzenes, fluorenones, sesquiterpenes and the like. The dendrobine is a pyrrolizidine derivative alkaloid which is extracted and separated from stems of dendrobium nobile (Dendro bium nobile Lindl) belonging to the family Orchidaceae, and has a molecular formula of C16H25NO2, a molecular weight of 263.27 and a melting point of 134.5-136 ℃. Experiments prove that the component has the effects of relieving pain and fever, reducing blood sugar, lowering blood pressure, regulating heart rate, treating Alzheimer's disease and the like. The polysaccharides of herba Dendrobii have effects of enhancing organism immunity and enhancing phagocytosis of abdominal cavity macrophage on chicken erythrocyte. The dendrobium nobile lindl has the functions of improving the nonspecific immunity of organisms and antagonizing the immunosuppression effect of cyclophosphamide, and the phagocytic function of macrophages is restored to a normal level. The dendrobium nobile lindl total alkali can obviously reduce the blood sugar level of patients with light and incipient diabetes, restore the blood sugar to normal, effectively reduce the blood sugar and the level of glycosylated hemoglobin, can dilate blood vessels, can reduce the vascular resistance of femoral artery and carotid artery, obviously improve the blood stasis symptom, reduce blood cholesterol and triglyceride, and improve the high-density lipoprotein cholesterol level, and is used for treating cardiovascular and cerebrovascular diseases and Alzheimer's disease. Herba Dendrobii can significantly increase SOD (superoxide dismutase) level, reduce LPO (lipid peroxide) to delay aging and resist oxidation, and has certain effects of improving intelligence and memory, and can be used for treating presenile dementia, neurasthenia and amnesia; one ester component contained in herba Dendrobii has effects of promoting blood circulation, removing blood stasis, treating thromboangiitis obliterans, cerebral thrombosis, and arteriosclerotic occlusion, and preventing organic change. In addition, the dendrobium alkaloid also has the effect of inhibiting or correcting the abnormal change of enzyme activity caused by galactose, and the dendrobium alkaloid has obvious improvement effect on tau protein abnormal hyperphosphorylation, GSK-3beta and inflammation at a site induced by lipopolysaccharide, so that the apoptosis of peripheral nerve cells of the hippocampus can be reduced, and the dendrobium alkaloid has obvious curative effect on the presenile dementia.
Astragalus root: the radix astragali contains saponin, flavone, etc., the saponin comprises radix astragali saponin I and II, radix astragali contains radix astragali saponin A, B, and radix astragali contains radix astragali saponin IV and soybean saponin I; the main components of the flavone are formononetin, calycosin and the like. Further contains amino acids, betaine, etc.; mongolian milkvetch root also contains astragalus polysaccharide I, II, III, etc. Radix astragali has effects of enhancing and regulating immunity, dilating blood vessel, inhibiting platelet aggregation, reducing blood viscosity, and improving blood circulation and brain perfusion, and contains microelements such as zinc. The astragalus has good effect of treating AD, the astragalus can induce BMSCs to differentiate into nerve cells in vitro, and the astragalus can induce BMSCs in vivo to treat AD, and has certain effect of preventing senile dementia.
Red sage root: is dried root and rhizome of Salvia miltiorrhiza Bge (Salvia militaria Bge.) belonging to Labiatae. The main functions are as follows: the function of the cardiovascular system, strengthening heart, enhancing myocardial contractility, improving cardiac function, without increasing myocardial oxygen consumption; has effects in dilating coronary artery and increasing myocardial blood flow; peripheral vessel dilation, increased blood flow; a decrease in cerebral blood flow; antithrombotic enhancement of plasmin activity; prolonged bleeding and clotting time; inhibition of platelet aggregation (increase of cAMP levels in platelets inhibits TXA2 synthesis); improving the rheological properties of blood (reduced blood viscosity, shortened time for red cell electrophoresis); improving microcirculation. The Saviae Miltiorrhizae radix is dried root and rhizome of Salvia miltiorrhiza Bunge (Salvia millirrhiza Bunge) of Salvia of Labiatae, and is frequently used in clinical treatment of AD. The salvia miltiorrhiza volatile oil has in-vitro antioxidant activity, an AD mouse model is built by adopting a method of intraperitoneal injection of D-gal and intragastric administration of AlCl _3, the anti-AD effect of the salvia miltiorrhiza volatile oil is explored, the learning capacity and the space memory capacity of an experimental AD model mouse are respectively determined by applying a Morris water maze experiment and a probe test on a behavioral level, the contents of Abeta, GFAP, BACE-1 and NEP related to the AD morbidity in the mouse brain are determined by applying western blot analysis (WB) and immunohistochemical analysis (IHC) on a protein level, the contents of MDA, ROS, SOD, GSH, AchE and Ach in the brain homogenate of the AD mouse are investigated by using Biochemical determinations on a molecular biological level, and the expression change of related inflammatory factors and Abeta related proteins in the AD mouse brain is investigated by applying an RT-PCR technology on a gene level. The mouse-like symptoms of AD caused by D-gal combined with AlCl 3 are inspected on the individual behavioral level, the molecular biological level, the protein level and the gene level, and the results show that the salvia volatile oil can obviously improve the learning ability and the memory ability of mice, obviously inhibit the expression abilities of Abeta, BACE-1 and GFAP related to the AD onset in hippocampal regions and cortical regions of the brains of the mice, promote the distribution of NEP in the hippocampal regions and cortical regions, obviously increase the contents of Ach and GSH and the activities of antioxidant enzymes SOD and CAT, and promote the gene expression levels of inflammatory reactions, inflammatory factors related to oxidative damage and related enzymes generated by Abeta in the brains of the mice to be reduced. The results show that in vivo and in vitro pharmacological experiments prove that the salvia miltiorrhiza volatile oil has stronger anti-inflammatory and antioxidant capabilities and can play a certain role in relieving and treating AD mouse-like symptoms caused by the combination of D-gal and AlCl _ 3.
Rhizoma polygonati: the rhizome contains steroid saponin, and 2 furostanol type saponins and 2 spirostanol type saponins are separated. The former is that: 26-O-beta-D-glucopyranosyl-22-O-methyl- (25) S-furost-5-ene-3 beta, 26-diol 3-O-beta-lycoris tetraglucoside (26-O-beta-D-glucopyranosyl-22-O-methyl-25 (S) -furost-5-ene-3 beta, 26-diol 3-O-beta-lycotetraoside) namely sibirian polygodide A (sibirioside-A) and 26-O-beta-glucopyranosyl-22-O-methyl-25 (S) -furost-5-ene-3 beta, 14 alpha, 26-triol 3-O-beta-lycoris tetraglucoside (26-O-beta-D-glucopyranosyl-22-O-beta-lycosyltetraoside) methyl-25(S) -fruost-5-ene-3 beta, 14 alpha, 26-triol 3-O-beta-lycotetraoside) namely 14 alpha-hydroxysibirioside A (14 alpha-hydroxysibirioside A); the ones belonging to the latter are: ((23S, 25R) spirost-5-ene-3 beta, 14 alpha, 23-triol 3-O-beta-lycotetraside), i.e., polyuria sibirica glycoside B (sibiricoside B) and neoparadiosgenin-A3-O-beta-lycoris tetraoside. The sealwort polysaccharide A, B, C is prepared by condensing glucose (glucose), mannose (mannose) and galacturonic acid (galacturonic acid) according to a molar ratio of 6:26: 1; and oligosaccharide A, B, C with relative molecular mass of 1630, 862 and 472, which is prepared by condensing fructose (fructose) and glucose at molar ratio of 8:1.4:1 and 2: 1. Rhizoma Polygonati has effects of increasing coronary blood flow, regulating blood lipid, lowering blood sugar, resisting aging and enhancing immunity. The modern clinic is used for treating coronary heart disease, hyperlipoidemia, diabetes, leukopenia, pulmonary tuberculosis, chronic hepatitis, mental and sleep deficiency, headache, senile dementia, deficiency of heart and spleen, deficiency of liver and kidney, weak muscles and bones, anorexia, dry mouth and other symptoms.
Ligusticum wallichii: it can be used for treating senile dementia, and is especially suitable for patients with stagnation of qi and blood stasis, and obstruction of cerebral collaterals. (1) The chemical components are as follows: containing ligustrazine (tetramethylpyrazine), loline or perindopril (1- (5-hydroxymethyl-2-furyl) -9h-pyrido [3, 4-b)]Indole [1- (5 hydroxymethy-2-furyl) -9H-pyrido [3,4-b ]]indole]Ligustilide, 3-butylidenephthalide, 3-butylidenebenzthalide-7-hydroxyphthalide, butylphthalide, (3S) -3-n-butyl-4-hydroxyphthalide [ (3S) -3-butyl-4-hydroxyphenylidenebenzthalide)]Namely (3S) -chuanxiongol ((3S) -chunxiongol), 3-n-butyl-3, 6,7-trihydroxy-4,5,6,7-tetrahydrophthalide (3-n-butyl-3, 6,7-trihydroxy-4,5,6,7-tetrahydrophthalide), neocnidide (neocin-dilide), senkyunolide (senkyunolide), B, C, D, E, F, G, H [ cis-6, 7-dihydroxy-ligustilide (cis-6, 7-dihydroxy-origniside ]]I [ trans-6, 7-hydroxyligustilide (trans-6, 7-dihydrox-yliggustilide) ]]、J[4]、K、L、M[6]、N[4]、O、P[8](E) -senkyunolide]E[4]Senkyunone, 2-methoxy-4- (3-methoxy-1-propenyl) phenol (2-methoxy-4- (3-methoxy-1-propenyl) phenol), 2-pentanoyl-benzyl ester [2- (1-oxypentyl) -benzoic acid methyl ester]5-hydroxymethyl-6-endo-3-methoxy-4-hydroxyphenyl-8-oxabicyclo [3.2.1]Oct-3-en-2-one [ 5-hydroxymethy-l-6-endo-3-methoxy-4-hydroxyphenyl-8-oxa-bicyclo (3.2.1) -oct-3-one][5]4-hydroxy-3-methoxyphenylhexene(4-hydroxy-3-methoxy styrene), 1-hydroxy-1- (3-methoxy-4-hydroxyphenyl) hexane [1-hydroxy-1- (3-methoxy-4-hydroxyphenyl) ethane]4-hydroxybenzoic acid (4-hydroxybenzoic acid), vanillic acid (vanillic acid), caffeic acid (coffeic acid), protocatechuic acid (protocatholic acid), ferulic acid (ferulic acid), chrysophanol (chrysophanic acid), sedanonic acid (sedanonic acid), L-isoleucyl-L-valine anhydride (L-isoleucyl-L-valine anhydride), L-valyl-L-valine anhydride (L-valyl-L-valinic acid anhydride), lol-valyl-L-valinic acid, loline (perlulaine), cnidium rhizome phenol, uracil (uracil), trimethylamine hydrochloride (trimethyamine-HCL), choline chloride (chlorinate), palmitic acid (palivitytic acid), vanillin (vanillin), 1-acyl-beta-carboline (1-beta-carboline), eudesmol (eudesmol), 1-acyl-beta-carboline (beta-carboline), eudesmol (eudesmol), linoleic acid (linoleic acid), dilinoleyl palmityl glyceride (dilinoyl palmityl glyceride), sucrose (sucrose), and the like. (2) The rhizome of Ligusticum wallichii contains volatile oil about 1%. The oil was identified to have 40 kinds of components, which accounted for 93.64% of the volatile oil, of which the main component was ligustilide (ligustilide) 58%, 3-butylidenephthalide 5.29%, and sabinene 6.08%, lactone compounds contained in the rhizome, including butenolide (butylidenephthalide), ligustilide (senkyunolide), neocnidilide (neocnidilide), 4-hydroxy-3-butylphthalide (4-hydroxy-3-buthyl phthalide), ligustilide (Chuanxingingol), ligustilide (2, 2' -diligurtilide), and 3-butyl-3, 6, ⒎ -4,5,6,7-tetrahydrophthalide, etc., in addition to the above-mentioned two kinds. The nitrogen-containing compounds include tetramethylpyrazine (tetramethylpyrazine, ligustrazine, chuanxinong gzine), perlyrine, trimethylamine hydrochloride, choline hydrochloride, L-isoleucyl-L-valine anhydride (L-isobutryl-L-valine anhydride), L-valyl-L-valine anhydride, 1-acetyl-beta-carboline, uracil, adenine and adenosine. the acidic or phenolic compounds include 4-hydroxy-3-methoxystyrene, 1-hydroxy-1- (3-methoxy-4-hydroxybenzene) -ethane, 4-hydroxybenzoic acid, caffeic acid, vanillic acid, ferulic acid (ferulaic acid), danamic acid (sadanic acid), rhein (chrysophanic acid), palmitic acid, vanillin and linoleic acid Sixteen kinds of,5,5 '-bifuranyl ether (bis-5, 5' -formyl furfuryl ether), sporular eucalyptol (spathulenol), beta-sitosterol, sucrose and a fatty acid glyceride. (3) Toxicity of Ligusticum wallichii: the LD50 of ligustrazine intravenous injection to mice is 239 mg/kg. The LD50 of the crude water-soluble preparation of chuanxiong rhizome to mice ip and im is 65.86 g/kg and 66.42g/kg respectively. The LD50 of ligustrazine mouse iv was 239 mg/kg. The mouse po ligustrazine is 5 mg/kg or 10mg/kg daily for 4 weeks, and no obvious abnormality is found in animal body weight, hemogram, liver and kidney function and pathological histological examination. (4) The pharmacological action of the ligusticum wallichii is as follows: a. has obvious tranquilizing effect on central nervous system, and small amount of volatile oil of rhizoma Ligustici Chuanxiong has effects of inhibiting animal brain activity, and exciting brain-extending respiratory center, blood vessel movement center and spinal cord reflex center, and the decoction of rhizoma Ligustici Chuanxiong can inhibit spontaneous activity of mouse ig and mouse ig, respectively, so that sleep time of mouse caused by pentobarbital sodium is prolonged, and caffeine (20mg/kg) can be resisted with exciting effect. But not against the convulsions of rats caused by pentaerythrine. The stomach is drenched with 25-50g/kg of rhizoma ligustici wallichii decoction, so that the spontaneous activity of a rat can be inhibited, and the sedation of the mouse is more obvious than that of the rat; it can also prolong the sleep time of pentobarbital, but can not antagonize the excitation of caffeine, and can not prevent the convulsion or lethal effect of pentamethylene tetrazole and cocaine. b. For treating cardiovascular diseases, rhizoma Ligustici Chuanxiong decoction is used for treating isolated Bufo siccus and frog heart at concentration of 10-5-10-4The amplitude of contraction is increased and the heart rate is slightly slower.
Licorice root: sweet and neutral in nature and flavor, enter heart, spleen, lung and stomach meridians. The liquorice contains various chemical components, the main components comprise glycyrrhizic acid, liquiritin and the like, the chemical composition of the liquorice is very complex, and the compounds separated from the liquorice at present comprise dozens of compounds such as glycyrrhizin, glycyrrhetinic acid, liquiritin, isoliquiritin, neoliquiritin, neoisoliquiritin, liquiritigenin, liquiritin, glyceol, isoliquiritigenin, 7-methyl coumarine, umbelliferone and the like, but the components and the quantity generally vary according to the type, planting area, harvesting time and other factors of the liquorice. A large number of researches show that glycyrrhizin and flavonoids are the most important physiological active substances in liquorice and mainly exist in the part inside the epidermis of liquorice root. The liquorice has the functions of regulating body immunity, resisting aging, inflammation and pathogenic microorganism, calming, resisting tumor, improving cardiovascular, tonifying spleen and qi, moistening lung and relieving cough, clearing heat and detoxicating, relieving pain, moderating drug property, eliminating phlegm and the like, and is used for treating weakness of spleen and stomach, shortness of breath and weakness, palpitation and severe palpitation, cough with little phlegm, toxic heat and pyocutaneous disease, medicine and food poisoning, abdominal and acute pain and limb contracture pain.
A Chinese medicinal composition for treating Alzheimer's disease and its preparation method are provided, which is characterized in that the dosage forms of the compound preparation include granule, dripping pill, nanometer preparation, decoction, tablet and capsule.
When the granule or the dropping pill is prepared, firstly, a liquorice extract, a mixed extract of astragalus and salvia miltiorrhiza, a mixed extract of polygonatum and ligusticum wallichii and a dendrobium nobile extract are respectively prepared, then the liquorice extract, the mixed extract of astragalus and salvia miltiorrhiza and the mixed extract of polygonatum and ligusticum wallichii are mixed and concentrated into a concentrated solution, and finally the dendrobium nobile extract and the concentrated solution are mixed and then added with an auxiliary agent to prepare a finished product.
Preferably, the preparation method of the liquorice extract comprises the following steps:
crushing liquorice into powder, adding water, performing ultrasonic treatment at low temperature of 0-10 ℃, rotation speed of 15000-30000 rpm and 50-60 Hz for 30-60 min, performing high-speed centrifugation, separating supernatant and precipitate, reserving the supernatant for later use, adding ethanol into the precipitate, performing low-temperature ultrasonic treatment for 15-30 min, performing suction filtration, washing filter residues with ethanol for 3-5 times, respectively collecting the filter residues and filtrate, and combining the filtrate and the supernatant to obtain a liquorice extracting solution.
Preferably, the preparation method of the mixed extract of the astragalus and the salvia comprises the following steps:
pulverizing radix astragali and Saviae Miltiorrhizae radix into powder, and placing the powder and Glycyrrhrizae radix residue for preparing Glycyrrhrizae radix extract in a decocting pot together at a solid-to-liquid ratio of 1: 4-8, adding deionized water, heating and boiling for 60-90 min under a reflux condition, adding ethanol with the same volume as the deionized water into a frying pan when the temperature is reduced to below 65 ℃, heating, carrying out micro-boiling reflux for 60-90 min, cooling to room temperature after the reaction is finished, and filtering with a 2.0-micrometer filter membrane to obtain primary filtrate; filtering the primary filtrate with 0.4 μm filter membrane to obtain mixed extractive solution of radix astragali and Saviae Miltiorrhizae radix.
Preferably, the preparation method of the mixed extract of rhizoma polygonati and ligusticum wallichii comprises the following steps:
pulverizing rhizoma Polygonati and rhizoma Ligustici Chuanxiong into powder, placing the powder and the residue obtained in the preparation of mixed extractive solution of radix astragali and Saviae Miltiorrhizae radix in a decocting pot, adding deionized water, heating to 95-100 deg.C, maintaining the temperature for 110-130 min, cooling to 55-65 deg.C, filtering with 2.0 μm filter membrane to obtain primary filtrate, and filtering with 0.4 μm filter membrane to obtain mixed extractive solution of rhizoma Polygonati and rhizoma Ligustici Chuanxiong.
Preferably, the licorice extract, the mixed extract of the astragalus root and the salvia miltiorrhiza and the mixed extract of the polygonatum rhizome and the ligusticum wallichii are stirred at a high speed, homogenized and mixed, and then concentrated into a mixed concentrated solution for later use. More preferably, the high speed stirring speed is 2900 revolutions per minute.
Preferably, the preparation method of the dendrobium nobile lindl extract comprises the following steps: the stem and flower of dendrobium nobile lindl are mixed according to the weight ratio of 5.0-6.5: 1.0-2.0, and grinding into powder, wherein the weight ratio of the raw materials is preferably 5.5: 1.5, taking the dendrobium nobile lindl powder under the conditions of extraction pressure of 5-l 0Mpa and extraction temperature of 15-25 ℃, and adopting CO2Performing supercritical extraction to obtain dendrobium nobile volatile oil, adding the residual dendrobium nobile dregs obtained by the supercritical extraction into ethanol, soaking for 90-120 min at 30-50 ℃, performing reflux extraction for 120-180 min at 65-85 ℃, concentrating the extracting solution into dendrobium nobile extract, and mixing the obtained dendrobium nobile volatile oil and the dendrobium nobile extract to obtain the dendrobium nobile mixed extract.
In the invention, the steps for preparing the finished product of the granule are as follows:
and (2) stirring and mixing the mixed concentrated solution of the astragalus, the salvia miltiorrhiza, the polygonatum, the ligusticum wallichii and the liquorice extract with the dendrobium nobile mixed extract at a high speed, wherein the stirring speed is 2900 r/min, adding the auxiliary agent during stirring and mixing, homogenizing again, putting the mixture into an ultrasonic instrument, carrying out ultrasonic treatment at 50-60 Hz for 20-30 min, then feeding the mixture into a granulator for granulation to obtain a semi-finished product of the traditional Chinese medicine granules, and drying the semi-finished product to obtain the finished product of the traditional Chinese medicine granules. Preferably, the auxiliary agent for preparing the granule is a mixture of hydroxypropyl cellulose, maltodextrin and xylitol according to the weight ratio of 0.2-0.5:0.5-1.0:1.0-2.0, and the total weight ratio of the auxiliary agent to the extracts of all the components of the traditional Chinese medicine is 8-9: 1-2.
In the invention, the steps for preparing the finished dripping pill product are as follows:
stirring and mixing the mixed concentrated solution of the astragalus, the salvia, the polygonatum, the ligusticum wallichii and the liquorice extract with the dendrobium nobile mixed extract at a high speed of 2900 r/min, adding an auxiliary agent during stirring and mixing, stirring and mixing uniformly at a high speed, homogenizing again, carrying out ultrasonic treatment at 60-80 Hz for 40-60 min, carrying out melting and heat preservation at the temperature of 60-95 ℃, then putting into a special dripping pill machine, dripping into a condensing agent at the speed of 40-70 drops per minute, forming the dripping pills, taking out, removing the condensing agent, and drying to obtain the dendrobium nobile lindl dripping pill. Wherein the adjuvant for preparing dripping pill is mixture of two or more of polyethylene glycol 6000, polyethylene glycol 4000, sodium stearate, Tween 80, insect wax, and hydrogenated vegetable oil. Preferably, the mixture of adjuvants is polyethylene glycol 6000: polyethylene glycol 4000: the insect wax is prepared by mixing 1.0-2.0: 2.0-3.0:0.1-0.5, wherein the weight ratio of the mixed concentrated solution of the astragalus root, the salvia miltiorrhiza, the sealwort, the ligusticum wallichii and the liquorice extract to the mixed extract of the dendrobium nobile and the auxiliary agent is 15-30: 0.5-1.0: 2.0-5.0, preferably 25: 1.0: 3.5.
the preparation method of the nano preparation, the decoction, the tablet and the capsule in the invention is a conventional technical method in the traditional Chinese medicine industry.
Compared with the prior art, the invention has the following advantages:
the medicine of the invention improves the cognitive function of the brain and prevents the development process of the Alzheimer disease through the ways of neurotransmitter, cerebral vasodilation, brain metabolism promoting drugs and the like. The compound traditional Chinese medicine for treating the Alzheimer disease realizes the improvement of the treatment effect of the medicine on the Alzheimer disease through the specific targeting effect and the mutual cross function among the components.
Detailed Description
The invention will be further described with reference to specific embodiments.
Example 1:
the weight parts of each component are as follows: 48 parts of dendrobium nobile, 18 parts of astragalus mongholicus, 18 parts of salvia miltiorrhiza, 7 parts of rhizoma polygonati, 7 parts of ligusticum wallichii and 2 parts of liquorice. Wherein, the dendrobium nobile lindl is prepared from dendrobium nobile lindl stems and dendrobium nobile flowers according to the weight ratio of 5.5: 1.5.
The preparation method of the granule comprises the following steps:
1) making herba Dendrobii, radix astragali, Saviae Miltiorrhizae radix, rhizoma Polygonati, rhizoma Ligustici Chuanxiong, and Glycyrrhrizae radix into standard Chinese medicinal decoction pieces;
2) preparing a liquorice extracting solution: crushing liquorice into powder, adding water, performing ultrasonic treatment at low temperature of 0-10 ℃, rotation speed of 15000-30000 rpm and 50-60 Hz for 30-60 min, performing high-speed centrifugation, separating supernatant and precipitate, keeping the supernatant for later use, adding ethanol into the precipitate, performing low-temperature ultrasonic treatment for 15-30 min, performing suction filtration, washing filter residues with ethanol for 3-5 times, respectively collecting the filter residues and filtrate, and combining the filtrate and the supernatant to obtain an extracting solution for later use;
3) preparing an extracting solution of astragalus and salvia: pulverizing radix astragali and radix Salviae Miltiorrhizae into powder, and placing the powder and the radix Glycyrrhizae residue obtained in step 2) in a frying pan together at a solid-to-liquid ratio of 1: 4-8, adding deionized water, heating and boiling for 60-90 min under a reflux condition, adding ethanol with the same volume as the deionized water into a frying pan when the temperature is reduced to below 65 ℃, heating, carrying out micro-boiling reflux for 60-90 min, cooling to room temperature after the reaction is finished, and filtering with a 2.0-micrometer filter membrane to obtain primary filtrate; filtering the primary filtrate with 0.4 μm filter membrane to obtain extractive solution;
4) preparing a polygonatum and ligusticum wallichii extracting solution, crushing the polygonatum and ligusticum wallichii into powder, putting the powder and the filter residue obtained in the step 3) into a frying pan together, adding deionized water, heating to 95-100 ℃, keeping the temperature for 110-130 minutes, cooling to 55-65 ℃, filtering with a 2.0 mu m filter membrane to obtain a primary filtrate, and filtering the primary filtrate with a 0.4 mu m filter membrane to obtain an extracting solution for later use;
5) preparing a mixed concentrated solution of astragalus, salvia miltiorrhiza, rhizoma polygonati, ligusticum wallichii and liquorice extract: stirring the extracting solution prepared in the step 2) to the step 4) at a high speed, homogenizing and mixing, and then concentrating to obtain a mixed concentrated solution for later use;
6) preparing a dendrobium nobile mixed extract: herba DendrobiiThe stem and the dendrobium stem flower are 5.5: 1.5 mixing and crushing into powder, taking the dendrobium nobile lindl powder under the conditions of extraction pressure of 5-l 0Mpa and extraction temperature of 15-25 ℃, and adopting CO2Performing supercritical extraction to obtain dendrobium nobile volatile oil, adding the residual dendrobium nobile dregs obtained by the supercritical extraction into ethanol, soaking for 90-120 min at 30-50 ℃, performing reflux extraction for 120-180 min at 65-85 ℃, concentrating the extracting solution into dendrobium nobile extract, and mixing the obtained dendrobium nobile volatile oil and the dendrobium nobile extract to obtain dendrobium nobile mixed extract for later use;
7) preparing granules: mixing the mixed concentrated solution of the astragalus, the salvia miltiorrhiza, the sealwort, the ligusticum wallichii and the liquorice extract with the dendrobium nobile mixed extract at a high speed, stirring at the rotating speed of 2900 revolutions per minute, adding an auxiliary agent in the stirring and mixing process, wherein the auxiliary agent is a mixture of hydroxypropyl cellulose, maltodextrin and xylitol according to the weight ratio of 0.2-0.5:0.5-1.0:1.0-2.0, and the total weight ratio of the auxiliary agent to all the extracts of the traditional Chinese medicines is 8-9: 1-2, homogenizing again after mixing uniformly, placing the mixture in an ultrasonic instrument for 20-30 min under 50-60 Hz ultrasonic treatment, then feeding the mixture into a granulator for granulation to obtain a semi-finished product of the traditional Chinese medicine granules, and drying the semi-finished product to obtain a finished product of the traditional Chinese medicine granules.
Example 2:
40 parts of dendrobium nobile, 20 parts of astragalus membranaceus, 20 parts of salvia miltiorrhiza, 8 parts of rhizoma polygonati, 8 parts of ligusticum wallichii and 4 parts of liquorice.
Wherein, the dendrobium nobile lindl is prepared from dendrobium nobile stems and dendrobium nobile flowers according to the weight ratio of 6.5: 2.0.
The preparation method of the granule comprises the following steps:
1) making herba Dendrobii, radix astragali, Saviae Miltiorrhizae radix, rhizoma Polygonati, rhizoma Ligustici Chuanxiong, and Glycyrrhrizae radix into standard Chinese medicinal decoction pieces;
2) preparing a liquorice extracting solution: crushing liquorice into powder, adding water, performing low-temperature ultrasonic treatment for 30-60 min, performing high-speed centrifugation, separating supernatant and precipitate, keeping the supernatant for later use, adding ethanol into the precipitate, performing low-temperature ultrasonic treatment for 15-30 min, performing suction filtration, washing filter residues with ethanol for 3-5 times, respectively collecting the filter residues and filtrate, and combining the filtrate and the supernatant to obtain an extracting solution for later use;
3) preparing an extracting solution of astragalus and salvia: pulverizing radix astragali and radix Salviae Miltiorrhizae into powder, and placing the powder and the radix Glycyrrhizae residue obtained in step 2) in a frying pan together at a solid-to-liquid ratio of 1: 4-8, adding deionized water, heating and boiling for 60-90 min under a reflux condition, adding ethanol with the same volume as the deionized water into a frying pan when the temperature is reduced to below 65 ℃, heating, carrying out micro-boiling reflux for 60-90 min, cooling to room temperature after the reaction is finished, and filtering with a 2.0-micrometer filter membrane to obtain primary filtrate; filtering the primary filtrate with 0.4 μm filter membrane to obtain extractive solution;
4) preparing a polygonatum and ligusticum wallichii extracting solution, crushing the polygonatum and ligusticum wallichii into powder, putting the powder and the filter residue obtained in the step 3) into a frying pan together, adding deionized water, heating to 95-100 ℃, keeping the temperature for 110-130 minutes, cooling to 55-65 ℃, filtering with a 2.0 mu m filter membrane to obtain a primary filtrate, and filtering the primary filtrate with a 0.4 mu m filter membrane to obtain an extracting solution for later use;
5) preparing a mixed concentrated solution of astragalus, salvia miltiorrhiza, rhizoma polygonati, ligusticum wallichii and liquorice extract: stirring the extracting solution prepared in the step 2) to the step 4) at a high speed, homogenizing and mixing, and then concentrating to obtain a mixed concentrated solution for later use;
6) preparing a dendrobium nobile mixed extract: the stem and flower of dendrobium nobile lindl are mixed according to the weight ratio of 6.5: 2.0, crushing into powder, taking the dendrobium nobile lindl powder under the conditions of extraction pressure of 5-l 0Mpa and extraction temperature of 15-25 ℃, and adopting CO2Performing supercritical extraction to obtain dendrobium nobile volatile oil, adding the residual dendrobium nobile dregs obtained by the supercritical extraction into ethanol, soaking for 90-120 min at 30-50 ℃, performing reflux extraction for 120-180 min at 65-85 ℃, concentrating the extracting solution into dendrobium nobile extract, and mixing the obtained dendrobium nobile volatile oil and the dendrobium nobile extract to obtain dendrobium nobile mixed extract for later use;
7) preparing granules: mixing the mixed concentrated solution of the astragalus, the salvia miltiorrhiza, the sealwort, the ligusticum wallichii and the liquorice extract with the dendrobium nobile mixed extract at a high speed, stirring at the rotating speed of 2900 revolutions per minute, adding an auxiliary agent in the stirring and mixing process, wherein the auxiliary agent is a mixture of hydroxypropyl cellulose, maltodextrin and xylitol according to the weight ratio of 0.2-0.5:0.5-1.0:1.0-2.0, and the total weight ratio of the auxiliary agent to all the extracts of the traditional Chinese medicines is 8-9: 1-2, homogenizing again after mixing uniformly, placing the mixture in an ultrasonic instrument for 20-30 min under 50-60 Hz ultrasonic treatment, then feeding the mixture into a granulator for granulation to obtain a semi-finished product of the traditional Chinese medicine granules, and drying the semi-finished product to obtain a finished product of the traditional Chinese medicine granules.
Example 3:
the weight parts of each component are as follows: 50 parts of dendrobium nobile lindl, 15 parts of astragalus membranaceus, 15 parts of salvia miltiorrhiza, 4 parts of rhizoma polygonati, 4 parts of ligusticum wallichii and 2 parts of liquorice, wherein the dendrobium nobile lindl is prepared from dendrobium nobile lindl stems and dendrobium nobile flowers according to the weight ratio of 5.0: 1.0.
The decoction prepared from the components comprises the following steps:
putting the raw materials in a decocting device according to the total raw materials: the weight ratio of water is 1.0: 3.0, boiling for 30 minutes for the first time, filtering by a filter bag with the diameter of 2.0 mu m, and reserving filtrate for later use; adding water into the first-time boiling filtration residue, boiling for 60 minutes, filtering with a 1.5-micron filter bag, and reserving the filtrate for later use; adding water into the second boiled and filtered decoction dregs, boiling for 90 minutes, filtering by a filter bag with the diameter of 1.0 mu m, and reserving the filtrate for later use; and finally, combining the three filtrates, placing the combined filtrates in a closed container for sterilization and filling, storing the combined filtrates at the temperature of 0-10 ℃, and taking out and heating the combined filtrates when drinking.
Example 4:
the weight parts of each component are as follows: 46.5 parts of dendrobium nobile lindl, 17.5 parts of astragalus membranaceus, 17.5 parts of salvia miltiorrhiza, 7.5 parts of rhizoma polygonati, 7.5 parts of ligusticum wallichii and 3.5 parts of liquorice, wherein the dendrobium nobile lindl is prepared from dendrobium nobile lindl stems and dendrobium nobile flowers according to the weight ratio of 6.5: 1.0.
The steps of preparing the components into the nanometer preparation are as follows: mixing the raw materials, placing the mixture into an ultrafine pulverizer to perform ultrafine grinding to 50-100nm ultrafine powder, and uniformly mixing the ultrafine powder and the powder by a powder mixer to obtain a finished product.
Test example: study on the efficacy of the finished product of the embodiment of the invention
Firstly, the finished product drug granules prepared in the embodiment 1 are used for rat gavage treatment.
1. Modeling for purchasing SPF-grade SD adult rats
Model animal strains: SPF grade SD rats, healthy, 250-300 g in body weight.
Grouping experiments: normal control group, model group, positive medicine group and tested medicine group.
The experimental period is as follows: 4-6 weeks.
2. The modeling method comprises the following steps: abeta perfusion model
2.1 the basic principle in view of the neurotoxic effects of A β, brain perfusion and deposition of A β can replicate the dementia model.
2.2 method of operation
SD rat is anesthetized with 3% sodium pentobarbital (40mg/kg), unhaired, skin sterilized and cut open, two holes (AP-3.5mm, Ml + -2.0 mm, Dv2.7mm) are symmetrically drilled on skull with dental drill to obtain injection point of CA3 region of hippocampus, and Abeta is injected into bilateral hippocampus1-28Fragments (2uL, 5nmol/uL), also can be injected unilaterally. Filling the empty needle with denture powder, suturing skin and sterilizing. Or perfusing the brain ventricle of the rat with Abeta by using a miniature osmotic pump or injecting Abeta into basal Nucleus (NB) of the rat1-40A polypeptide.
2.3 Observation of indicators
1) Focal necrosis, neuronal loss and gliosis can be seen at the site of brain injection in experimental animals, leading to neuronal degeneration.
2) Injecting Abeta into human hippocampus to form a dementia model, detecting whether staining positive substances precipitate at an injection part by Congo red staining test, indicating that dystrophic axons appear by silver staining compared with the method of Xiaoshfski, and after injecting Abeta for 1 month, obviously losing neurons in the hippocampus by naked eyes, especially in dentate gyrus.
3) The brain ventricle of the rat is perfused with A beta by a miniature osmotic pressure pump, and the rat cognitive function is proved to be damaged by water maze and passive avoidance test, and the activity of choline acetyltransferase in the anterior cortex of the brain and the hippocampus is obviously reduced, and the results show that the A beta perfusion causes the dysfunction of the central nervous system.
4) Injection of Abeta into basal Nuclei (NB) of rats1-40The polypeptide is determined to have plaque formation at an injection part through NissL staining and A beta immunoreaction, and is accompanied with cholinergic hypofunction, cholinergic neuron of basal nucleus is reduced, and Ach release is reduced.
5) Unilateral and bilateral hippocampal injection of Abeta1-28Fragment (2ul, 5 n)mol/uL), the results of behavior experiments show that the injected Abeta reduces the mental motor coordination ability (PMC), and meanwhile, passive avoidance experiments show that the learning acquisition ability is damaged after the Abeta is injected, and the passive avoidance times are reduced. The above results show that a β perfusion is associated with impairment of learning and memory functions and neuronal degeneration and loss.
2.4 model modeling of AD rats is successful
The model not only shows the abnormity of passive reflection behavior, but also has prominent spatial resolution obstacle. Pathologically, the model not only has the characteristics of reduced number of neurons, reduced positive ChAT immunoreaction cells, but also has the characteristics of amyloid deposition of blood vessel walls, nerve fiber filaments, glial cell hyperplasia, increased generation of inflammatory mediators and the like, and is closer to the pathological characteristics of AD to a certain extent. Can be used as a means for researching the pathological mechanism of AD and evaluating therapeutic drugs. The model has short induction period and good repeatability, and can save the dosage of Abeta by injecting into hippocampus.
3. Aiming at AD rat model rats, the dosage of the finished product medicinal granule is calculated according to kilogram body weight for intragastric administration, the dosage is three dosages of low dosage and medium dosage, the dosage is conventional dosage, the dosage is 0.125g/250g, and the dosage is 2 times of the low dosage. The high dose is 4 times of the low dose, the stomach filling is carried out for one week, the stomach filling method uses a disposable syringe to suck medicine and uses a stomach filling needle to fill the stomach according to the conventional method, then the behavior change condition of the rat in the Morry water maze is tested, the space learning memory ability of the rat is tested, the result shows that the low and medium doses can obviously improve the space learning ability of the model rat, particularly the time for the model rat to search a platform is obviously shortened when the Morry water maze is tested, the search strategy is also improved, and the disordered and unchangeable mode is changed into the trend search.
4. Performing heart perfusion on the model rats and the control group, and taking the brains of the model rats and the control group to perform tau protein phosphorylation level, expression levels of methylated PP2Ac and methylase/demethylase, and expression levels of Abeta-40 and Abeta-42; meanwhile, taking the hippocampus of other rats treated in the same way, and detecting the phosphorylation level of each site of tau protein, the expression level of methylated PP2Ac and methylase/demethylase and the expression level of Abeta-40 and Abeta-42 in the hippocampus by using a Western blot experiment technology, thereby discussing and clarifying the treatment mechanism and the treatment effect. NFTs caused by hyperphosphorylation of Tau protein are one of the major pathological features of the brain in AD. The research proves that the phosphorylation sites on the Tau protein molecules are more than 30, the Tau protein molecules in normal brain contain 2-4 phosphate groups, and each Tau protein molecule can contain 6-12 phosphate groups in the brain of AD patients due to hyperphosphorylation of the Tau protein. Hyperphosphorylated Tau protein loses its normal physiological function, resulting in neurofibrillary tangles, causing impaired nerve axonal transport, causing synaptic loss, neuronal damage, and ultimately, cerebral neurodegeneration in AD patients. Post-translational modifications of proteins have a significant impact on protein function. In normal brain, Tau protein phosphorylation and dephosphorylation are in equilibrium under the combined action of protein kinase and protein phosphatase. With the change of the apparent conditions such as age, environment, nutritional status, etc., the balance may be broken, causing the enhancement of the related protein kinase, the weakening of the protein phosphatase, and the hyperphosphorylation of Tau protein. There are a wide variety of protein kinases and protein phosphatases that regulate protein phosphorylation and dephosphorylation. The Tau protein phosphatases are mainly classified into Phosphoprotein Phosphatases (PPs) and phosphotyrosinase (PTPs). Among them, the substrate amino acid residue for dephosphorylation of PPs is serine/threonine residue, and mainly includes various subtypes such as PP1, PP2A, PP2B, PP4, PP5, etc., and plays a major role in the dephosphorylation process of phosphorylated Tau (p-Tau) protein. Therefore, PP2A is considered as a key phosphatase for dephosphorylation of p-Tau protein, and activity change of PP2A is closely related to pathological process of AD.
The result shows that the finished medicine of the invention can reduce the demethylase PME and the demethylation and phosphorylation levels of PP2Ac, and simultaneously can reduce the phosphorylation level of the Thr668 site of APP and inhibit the expression level of Abeta-40. The Tau protein molecule in the model rat is reduced from the original 11 phosphate groups to 4 phosphate groups, reaching the normal level. In the total dephosphorylation of phosphorylated Tau protein, the PP2A action accounted for 69.235% and the sum of the other protein phosphatases accounted for 30.765%. The phosphorylation sites on the Tau protein molecule are reduced from the original 35 to 21, and the value returns to the normal value.
5. A clean SD adult rat is purchased, the dosage of the finished product medicinal granule is calculated according to kilogram body weight, the stomach is irrigated, the blood concentration of the finished product medicinal granule with higher concentration in the blood of the rat is kept, and the aim of treating the Alzheimer disease is fulfilled by using the medicament.
6. Injecting Wortmannine + GFX which is a tool medicine capable of causing the activity of protein kinase GSK-3beta to be increased and 0A which is a tool medicine capable of causing the activity of PP2Ac to be reduced into the ventriculus cerebralis of the SD rat with gastric perfusion, and preparing an Alzheimer disease rat model with the activity of protein kinase GSK-3beta in hippocampal tissues and the activity of protein phosphatase PP2Ac to be reduced.
The above mechanism can illustrate the therapeutic mechanism of the compound preparation of the invention for treating Alzheimer disease.
Secondly, the traditional Chinese medicine formula for treating the Alzheimer disease is added, added or replaced according to the traditional Chinese medicine compound formula, and the contrast test of the effect of treating the Alzheimer disease is carried out
The method for researching the drug effect of the finished product in the embodiment of the invention is adopted to evaluate the drug effect, the components in the formula of the invention are added, subtracted or replaced under the same test method and the same environmental conditions, and the components are prepared into granules or dropping pills, and the change of the research and treatment effect is observed.
The evaluation results of the specific formula addition change or substitution change and the treatment effect on the Alzheimer disease after the formula addition change or substitution change are shown in the following tables (tables 1 and 2):
table 1: prescription addition, subtraction or replacement change table
Wherein, the dendrobium nobile lindl is prepared from dendrobium nobile stems and dendrobium nobile flowers according to the weight ratio of 5.0-6.5: 1.0-2.0. Preferably 5.5: 1.5.
table 2: evaluation of treatment effect of the composition on treating Alzheimer's disease after addition, subtraction or replacement of the composition
The traditional Chinese medicine formula for treating the Alzheimer disease is compounded according to the theory of traditional Chinese medicines and the principle of monarch, minister, assistant and guide, the dendrobium nobile is monarch drug, the astragalus and the red sage root are ministerial drugs, the ligusticum wallichii and the rhizoma polygonati are assistant drugs, and the liquorice is a conductant drug. The compound traditional Chinese medicine is prepared by adopting modern new traditional Chinese medicine technology and based on the pharmacological screening of modern traditional Chinese medicines, and the medicine improves the cognitive function of the brain and prevents the development process of the Alzheimer disease through the ways of neurotransmitter, cerebral vasodilation, brain metabolism promoting medicines and the like. The invention realizes the improvement of the treatment effect of the medicament on the Alzheimer disease through the specific targeting action and the mutual cross function among the components. The interaction and cross effect among the traditional Chinese medicine components are realized based on the basic principle, the action and the efficacy of the traditional Chinese medicine formula and the analysis of the components of the modern traditional Chinese medicine, the targeting action of the medicine, the efficacy and the toxicological evaluation and the like. The traditional Chinese medicine composition has obvious effects of improving and treating symptoms caused by the Alzheimer disease, has short treatment course, quick response, safety and no toxic or side effect, and can be widely applied to clinical treatment of the Alzheimer disease.
Claims (10)
1. The traditional Chinese medicine for treating the Alzheimer disease is characterized by comprising the following components in parts by weight:
40-50 parts of dendrobium nobile, 15-20 parts of astragalus membranaceus, 15-20 parts of salvia miltiorrhiza, 4-8 parts of rhizoma polygonati, 4-8 parts of ligusticum wallichii and 2-4 parts of liquorice, wherein the dendrobium nobile consists of dendrobium stem and dendrobium nobile flowers, and the weight ratio of the dendrobium stem to the dendrobium nobile flowers is 5.0-6.5: 1.0-2.0.
2. The traditional Chinese medicine for treating Alzheimer's disease according to claim 1, which is characterized by comprising the following components in parts by weight:
48 parts of dendrobium nobile lindl, 18 parts of astragalus membranaceus, 18 parts of salvia miltiorrhiza, 7 parts of polygonatum sibiricum, 7 parts of ligusticum wallichii and 2 parts of liquorice, wherein the dendrobium nobile lindl consists of dendrobium nobile stems and dendrobium nobile flowers, and the weight ratio of the dendrobium nobile stems to the dendrobium nobile flowers is 5.5: 1.5.
3. a method for preparing a compound Chinese medicine preparation for treating Alzheimer's disease according to claim 1, wherein the dosage form of the compound preparation comprises granules, dripping pills, nano preparations, decoctions, tablets and capsules.
4. The method for preparing a compound Chinese medicinal preparation for treating Alzheimer's disease according to claim 3, wherein the granule or drop pill is prepared by respectively preparing radix Glycyrrhizae extractive solution, radix astragali and radix Salviae Miltiorrhizae extractive solution, rhizoma Polygonati and rhizoma Chuanxiong extractive solution, and herba Dendrobii extract, mixing radix Glycyrrhizae extractive solution, radix astragali and radix Salviae Miltiorrhizae extractive solution, and rhizoma Polygonati and rhizoma Chuanxiong extractive solution, concentrating, mixing herba Dendrobii extract and concentrated solution, and adding adjuvant to obtain the final product.
5. The preparation method of the compound traditional Chinese medicine preparation for treating Alzheimer's disease according to claim 4, wherein the preparation method of the liquorice extract, the mixed extract of radix astragali and Salvia miltiorrhiza, the mixed extract of rhizoma Polygonati and rhizoma Ligustici Chuanxiong, and the Dendrobium nobile extract comprises the following steps:
1) preparing a liquorice extracting solution: crushing liquorice into powder, adding water, performing ultrasonic treatment at low temperature of 0-10 ℃, rotation speed of 15000-30000 rpm and 50-60 Hz for 30-60 min, performing high-speed centrifugation, separating supernatant and precipitate, reserving the supernatant for later use, adding ethanol into the precipitate, performing low-temperature ultrasonic treatment for 15-30 min, performing suction filtration, washing filter residues with ethanol for 3-5 times, respectively collecting the filter residues and filtrate, and combining the filtrate and the supernatant to obtain a liquorice extracting solution;
2) preparing a mixed extracting solution of astragalus and salvia: pulverizing radix astragali and radix salviae miltiorrhizae into powder, putting the powder and the licorice residue obtained in the step 1) into a frying pan together, and mixing the powder and the licorice residue according to a solid-liquid ratio of 1: 4-8, adding deionized water, heating and boiling for 60-90 min under a reflux condition, adding ethanol with the same volume as the deionized water into a frying pan when the temperature is reduced to below 65 ℃, heating, carrying out micro-boiling reflux for 60-90 min, cooling to room temperature after the reaction is finished, and filtering with a 2.0-micrometer filter membrane to obtain primary filtrate; filtering the primary filtrate with 0.4 μm filter membrane to obtain mixed extractive solution of radix astragali and Saviae Miltiorrhizae radix;
3) preparing a mixed extracting solution of rhizoma polygonati and ligusticum wallichii: pulverizing rhizoma polygonati and ligusticum wallichii into powder, putting the powder and the filter residue obtained in the step 2) into a frying pan together, adding deionized water, heating to 95-100 ℃, keeping the temperature for 110-130 minutes, cooling to 55-65 ℃, filtering with a 2.0 mu m filter membrane to obtain primary filtrate, and filtering the primary filtrate with a 0.4 mu m filter membrane to obtain a mixed extract of the rhizoma polygonati and the ligusticum wallichii;
4) preparing the dendrobium nobile extract: the stem and flower of dendrobium nobile lindl are mixed according to the weight ratio of 5.0-6.5: 1.0-2.0, crushing into powder, taking the dendrobium nobile lindl powder under the conditions of extraction pressure of 5-l 0Mpa and extraction temperature of 15-25 ℃, and adopting CO2Performing supercritical extraction to obtain dendrobium nobile volatile oil, adding the residual dendrobium nobile dregs obtained by the supercritical extraction into ethanol, soaking for 90-120 min at 30-50 ℃, performing reflux extraction for 120-180 min at 65-85 ℃, concentrating the extracting solution into dendrobium nobile extract, and mixing the obtained dendrobium nobile volatile oil and the dendrobium nobile extract to obtain the dendrobium nobile mixed extract.
6. The preparation method of the compound traditional Chinese medicine preparation for treating alzheimer disease as claimed in claim 3, wherein the preparation steps of the compound preparation as a finished granule product are as follows:
mixing and concentrating a liquorice extract, a mixed extract of astragalus and salvia miltiorrhiza and a mixed extract of polygonatum and ligusticum wallichii into a mixed concentrated solution, then stirring and mixing the mixed concentrated solution with the dendrobium nobile at a high speed, wherein the stirring speed is 2900 r/min, adding an auxiliary agent during stirring and mixing, homogenizing again, placing the mixture in an ultrasonic instrument for ultrasonic treatment at 50-60 Hz for 20-30 min, then feeding the mixture into a granulator for granulation to obtain a semi-finished product of traditional Chinese medicine granules, and drying the semi-finished product to obtain a finished product of the traditional Chinese medicine granules.
7. The method for preparing a compound Chinese medicine preparation for treating alzheimer's disease as claimed in claim 6, wherein the adjuvant for preparing the granule is a mixture of hydroxypropyl cellulose, maltodextrin and xylitol in a weight ratio of 0.2-0.5:0.5-1.0:1.0-2.0, and the total weight ratio of the adjuvant to the total extracts of all the Chinese medicinal materials is 8-9: 1-2.
8. The preparation method of the compound traditional Chinese medicine preparation for treating Alzheimer's disease according to claim 3, wherein the preparation method of the compound preparation as a finished product of dripping pills comprises the following steps:
mixing and concentrating a liquorice extract, a mixed extract of astragalus and salvia miltiorrhiza and a mixed extract of polygonatum and ligusticum wallichii into a mixed concentrated solution, then stirring and mixing the mixed concentrated solution with a dendrobium nobile at a high speed of 2900 r/min, uniformly stirring and mixing the added auxiliary agents while stirring, homogenizing again, carrying out ultrasonic treatment for 40-60 min at 60-80 Hz, carrying out melting and heat preservation at the temperature of 60-95 ℃, then putting the mixed solution into a special dropping pill machine, dripping the mixed solution into a condensing agent at the speed of 40-70 drops per minute, forming the dropping pill, taking out, removing the condensing agent, and drying to obtain the finished product.
9. The method for preparing a compound Chinese medicinal preparation for treating alzheimer's disease according to claim 8, wherein the adjuvant for preparing the dripping pill is a mixture of any two or more of polyethylene glycol 6000, polyethylene glycol 4000, sodium stearate, tween 80, insect wax and hydrogenated vegetable oil.
10. The preparation method of the compound traditional Chinese medicine preparation for treating alzheimer disease according to claim 9, characterized in that the weight ratio of each component of the adjuvant is polyethylene glycol 6000: polyethylene glycol 4000: the insect wax is 1.0-2.0: 2.0-3.0:0.1-0.5, wherein the weight ratio of the mixed concentrated solution of the astragalus root, the salvia miltiorrhiza, the sealwort, the szechuan lovage rhizome and the liquorice extract to the mixed extract of the dendrobium nobile and the auxiliary agent is 15-30: 0.5-1.0: 2.0-5.0.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110786360.9A CN113413439B (en) | 2021-07-12 | 2021-07-12 | Traditional Chinese medicine formula for treating Alzheimer's disease and preparation method of compound preparation of traditional Chinese medicine formula |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110786360.9A CN113413439B (en) | 2021-07-12 | 2021-07-12 | Traditional Chinese medicine formula for treating Alzheimer's disease and preparation method of compound preparation of traditional Chinese medicine formula |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113413439A CN113413439A (en) | 2021-09-21 |
CN113413439B true CN113413439B (en) | 2022-03-29 |
Family
ID=77720785
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110786360.9A Active CN113413439B (en) | 2021-07-12 | 2021-07-12 | Traditional Chinese medicine formula for treating Alzheimer's disease and preparation method of compound preparation of traditional Chinese medicine formula |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113413439B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114767670B (en) * | 2022-05-06 | 2024-01-30 | 遵义医科大学 | Application of dendrobium nobile alkaloid |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1552415A (en) * | 2003-06-03 | 2004-12-08 | 天津天士力制药股份有限公司 | Medicine for treating dementia and preparing method thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100522210C (en) * | 2004-12-10 | 2009-08-05 | 天津天士力制药股份有限公司 | Medicinal composition for treating aphronesia and preparing process thereof |
CN108669531A (en) * | 2018-03-29 | 2018-10-19 | 遵义医学院 | A kind of HERBA DENDROBII powder and its application |
-
2021
- 2021-07-12 CN CN202110786360.9A patent/CN113413439B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1552415A (en) * | 2003-06-03 | 2004-12-08 | 天津天士力制药股份有限公司 | Medicine for treating dementia and preparing method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN113413439A (en) | 2021-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113577230A (en) | Composition for preventing and delaying occurrence and development of senile dementia and application thereof | |
KR101855821B1 (en) | Composition for relieving of menopausal symptoms and improving blood circulation | |
KR20090109446A (en) | The composition comprising complex herbal extract as an active ingredient and the preparation method thereof | |
Liang et al. | Carthamus tinctorius L.: a natural neuroprotective source for anti-Alzheimer's disease drugs | |
Tan et al. | Research progress in traditional Chinese medicine in the treatment of Alzheimer’s disease and related dementias | |
CN113413439B (en) | Traditional Chinese medicine formula for treating Alzheimer's disease and preparation method of compound preparation of traditional Chinese medicine formula | |
CN109925402B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
CN106581335A (en) | Medicine composition for treating Alzheimer's disease and preparing method and application thereof | |
CN1923227B (en) | Traditional Chinese medicinal formulation for treating ischemic cardiovascular and cerebrovascular diseases and preparation method thereof | |
KR101451754B1 (en) | A composition for preventing bone metabolism-related diseases and increasing bone function comprising mix extracts of lycium root bark and dipsacus asper wall | |
KR100700065B1 (en) | A composition of chinese drugs having neuro-protecting activity | |
CN104027428B (en) | Preparation method of traditional Chinese medicine compound and application of traditional Chinese medicine compound in prevention and treatment of senile dementia | |
CN107106624A (en) | Prevention, the composition for the mixed extract containing mulberries and fuling peel for improving or treating degenerative neural disease | |
KR20100082044A (en) | Composition comprising the extract of zingiberis rhizoma crudus or zingiberis siccatum rhizoma for prevention and treatment of memory and cognitive impairments involved disorders | |
KR101451755B1 (en) | A composition for preventing bone metabolism-related diseases and increasing bone function comprising mix extracts of Mori Fructus and Aralia Continentalis | |
KR101228920B1 (en) | A composition comprising of a leaf extract of dendropanax morbifera for treating and preventing intestinal function disorder | |
CN108126160B (en) | Traditional Chinese medicine composition, traditional Chinese medicine health tea, preparation method and application thereof | |
KR101154220B1 (en) | Composition comprising the powder of a fermented Chungkukjang or the extracted fraction of a fermented Chungkukjang for treating and preventing ischemia damage disease | |
CN107106620A (en) | Prevention, the composition for the bark extract containing Poria cocos for improving or treating degenerative neural disease | |
WO2005049058A1 (en) | Radix salviae miltiorrhizae, extract and composition thereof for the treatment of the aspirin resistance diseases | |
CN105616839B (en) | A kind of herbal medicine efficacy component compound with antidepressant effect | |
CN101020016A (en) | Medicine for treating fracture and injured tendon and its prepn | |
CN103768171A (en) | Traditional Chinese medicinal composition for resisting depression, sterilizing and disinfecting and preparation method of composition | |
CN103768349B (en) | Application in preparation treatment cerebrovascular and relevant disease medicine for the four taste Fructus cinnamomi camphorae preparations | |
KR101423875B1 (en) | A composition comprising the complex extract for preventing or treating stroke and degenerative brain disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |